Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

Recombinant plasmid DNA and attenuated poxviruses are under development as cancer and infectious disease vaccines. We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epi...

Full description

Bibliographic Details
Main Authors:	Smith, C, Dunbar, P, Mirza, F, Palmowski, M, Shepherd, D, Gilbert, S, Coulie, P, Schneider, J, Hoffman, E, Hawkins, R, Harris, A, Cerundolo, V
Format:	Journal article
Language:	English
Published:	2005

Similar Items

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
by: Smith, C, et al.
Published: (2005)

Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions.
by: Salio, M, et al.
Published: (2003)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
by: Hanke, T, et al.
Published: (1998)

Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma.
by: Dunbar, P, et al.
Published: (1999)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
by: Sharpe, S, et al.
Published: (2003)

A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.
by: Dunbar, P, et al.
Published: (2000)

The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
by: Palmowski, M, et al.
Published: (2002)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Immunotherapy of melanoma.
by: Smith, C, et al.
Published: (2001)

Competition between CTL narrows the immune response induced by prime-boost vaccination protocols.
by: Palmowski, M, et al.
Published: (2002)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
by: McShane, H, et al.
Published: (2004)

Circulating melanoma cells and survival in metastatic melanoma.
by: Rao, C, et al.
Published: (2011)

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
by: Allen, T, et al.
Published: (2000)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
by: Gilbert, S, et al.
Published: (1999)

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
by: Dangoor, A, et al.
Published: (2010)

The SETDB1 histone methyltransferase is recurrently amplified in and accelerates melanoma
by: Ceol, Craig J., et al.
Published: (2012)

Malignant melanoma and bone resorption.
by: Lau, Y, et al.
Published: (2006)

Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
by: Hermans, I, et al.
Published: (2003)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
by: Moorthy, V, et al.
Published: (2003)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
by: McConkey, S, et al.
Published: (2003)

Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
by: Maczek, C, et al.
Published: (2005)

Anorectal melanoma.
by: Jalleh, R.P., et al.
Published: (1988)

DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice.
by: Hanke, T, et al.
Published: (1998)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
by: Reyes-Sandoval, A, et al.
Published: (2010)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
by: Behboudi, S, et al.
Published: (2004)

Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
by: Valmori, D, et al.
Published: (2000)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
by: Dorrell, L, et al.
Published: (2000)

Role of the proteasome and non proteasomal proteases in the generation of CTL epitopes.
by: Cerundolo, V, et al.
Published: (1998)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
by: Mcshane, H, et al.
Published: (2001)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Cottingham, M, et al.
Published: (2008)

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
by: Schneider, J, et al.
Published: (2001)

Erratum: Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
by: Reyes-Sandoval, A, et al.
Published: (2011)

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
by: Walther, M, et al.
Published: (2006)

Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
by: Gileadi, U, et al.
Published: (1999)

Association of known melanoma risk factors with primary melanoma of the scalp and neck
by: Wood, RP, et al.
Published: (2020)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
by: McConkey, S, et al.
Published: (2003)

Melanoma: markers and epigenetics
by: Goding, C
Published: (2007)

Editorial: melanomas and Wnts.
by: Goding, C
Published: (2005)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
by: Alharbi, N
Published: (2014)